ReviewThe Lancet. Infectious diseases2023
How can lessons from the COVID-19 pandemic enhance antimicrobial resistance surveillance and stewardship?
Review in The Lancet. Infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Discovery of potent biphenyl-macolacin derivatives through a lysine-T/CDHA iterative scanning (LTIS) strategy followed by chemical ligation-based modifications.Molecular diversity · 2026Article
- Shift of antibiotic resistance after the COVID-19 pandemic: results from the INVIFAR Network.JAC-antimicrobial resistance · 2026Article
- Containing a PER-1-producingInfection prevention in practice · 2026Article
- Temporal Trends in Antibiotic Resistance of Klebsiella pneumoniae and Antibiotic Consumption: A Six-year Longitudinal Surveillance Study : Temporal Trends of Resistance and Consumption of Antibiotics to K. pneumoniae.Journal of epidemiology and global health · 2026Article
- Inclusion of antimicrobial resistance in a pandemic agreement: why it matters and what comes next?Health affairs scholar · 2026Review
- A novel synergistic action of phage vB_PaeP_GZMU_A1002 with allicin against carbapenem-resistant Pseudomonas aeruginosa.Biology direct · 2026Article
- Trends in antimicrobial resistance education research: a bibliometric analysis.One health (Amsterdam, Netherlands) · 2025Review
- The Impact of the COVID-19 Pandemic on Antimicrobial Resistance Trends in a Tertiary Care Teaching Hospital: A Ten-Year Surveillance Study.Antibiotics (Basel, Switzerland) · 2025Article
- Assembly and inhibition of transferable TMexCD1-TOprJ1 efflux pump.Nature communications · 2025Article
- A Retrospective Study of the Impact of the COVID-19 Pandemic on the Utilization and Quality of Antibiotic Use in a Tertiary Care Teaching Hospital in Low-Resource Settings.Antibiotics (Basel, Switzerland) · 2025Article
- Bacterial Superinfections After SARS-CoV-2 Pneumonia: Antimicrobial Resistance Patterns, Impact on Inflammatory Profiles, Severity Scores, and Clinical Outcomes.Diseases (Basel, Switzerland) · 2025Article
- Epidemiological and Antimicrobial Resistance Trends ofInfection and drug resistance · 2025Article
- Overview of antimicrobial resistance mitigation efforts in Benin 2024.Journal of public health in Africa · 2025Article
- Molecular pathogen profiling of COVID-19 coinfections.BMC infectious diseases · 2024Article
- The impact of the COVID-19 pandemic on the antimicrobial stewardship workforce in Scottish acute care hospitals-a qualitative study.JAC-antimicrobial resistance · 2024Article
- Perspectives on the Regional Strategy for Implementation of National Action Plans on Antimicrobial Resistance in the WHO African Region.Antibiotics (Basel, Switzerland) · 2024Article
- Returned Rate and Changed Patterns of Systemic Antibiotic Use in Ambulatory Care in Hungary after the Pandemic-A Longitudinal Ecological Study.Antibiotics (Basel, Switzerland) · 2024Article
- An inhibitory mechanism of AasS, an exogenous fatty acid scavenger: Implications for re-sensitization of FAS II antimicrobials.PLoS pathogens · 2024Article
- Screening ofAntibiotics (Basel, Switzerland) · 2024Article
- Multiple impacts of the COVID-19 pandemic and antimicrobial stewardship on antimicrobial resistance in nosocomial infections: an interrupted time series analysis.Frontiers in public health · 2024Article
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
Abstract
COVID-19 demanded urgent and immediate global attention, during which other public health crises such as antimicrobial resistance (AMR) increased silently, undermining patient safety and the life-saving ability of several antimicrobials. In 2019, WHO declared AMR a top ten global public health threat facing humanity, with misuse and overuse of antimicrobials as the main drivers in the development of antimicrobial-resistant pathogens. AMR is steadily on the rise, especially in low-income and middle-income countries across south Asia, South America, and Africa. Extraordinary circumstances often demand an extraordinary response as did the COVID-19 pandemic, underscoring the fragility of health systems across the world and forcing governments and global agencies to think creatively. The key strategies that helped to contain the increasing SARS-CoV-2 infections included a focus on centralised governance with localised implementation, evidence-based risk communication and community engagement, use of technological methods for tracking and accountability, extensive expansion of access to diagnostics, and a global adult vaccination programme. The extensive and indiscriminate use of antimicrobials to treat patients, particularly in the early phase of the pandemic, have adversely affected AMR stewardship practices. However, there were important lessons learnt during the pandemic, which can be leveraged to strengthen surveillance and stewardship, and revitalise efforts to address the AMR crisis.
Indexed as
Identifiers
37290476What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.